Parkinson Disease: Functional Assessment, Gene Disruptions, and More

New Parkinson disease studies offer insights into topics such as LRRK2 G2019S transgene activity, preclinical drug development, and neuroprotection in Parkinson disease.

Related Videos
Related Content

NeurologyLive® Friday 5 — March 31, 2023

March 31st 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

This Week on NeurologyLive® — March 27, 2023

March 27th 2023

Episode 81: Widening the Therapeutic Window in Parkinson Disease

January 27th 2023

NeurologyLive® Friday 5 — March 24, 2023

March 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023

NeurologyLive® Friday 5 — March 31, 2023

March 31st 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

This Week on NeurologyLive® — March 27, 2023

March 27th 2023

Episode 81: Widening the Therapeutic Window in Parkinson Disease

January 27th 2023

NeurologyLive® Friday 5 — March 24, 2023

March 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023

NeurologyLive® Friday 5 — March 31, 2023

March 31st 2023

Episode 84: Parkinson Disease Education for Community Providers

March 10th 2023

This Week on NeurologyLive® — March 27, 2023

March 27th 2023

Episode 81: Widening the Therapeutic Window in Parkinson Disease

January 27th 2023

NeurologyLive® Friday 5 — March 24, 2023

March 24th 2023

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.